Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 53.79
NAS:AAAP's Cash-to-Debt is ranked lower than
51% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. NAS:AAAP: 53.79 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:AAAP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.48  Med: 4.09 Max: No Debt
Current: 53.79
0.48
No Debt
Equity-to-Asset 0.68
NAS:AAAP's Equity-to-Asset is ranked lower than
51% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:AAAP: 0.68 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:AAAP' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.39  Med: 0.61 Max: 0.72
Current: 0.68
0.39
0.72
Debt-to-Equity 0.01
NAS:AAAP's Debt-to-Equity is ranked higher than
95% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:AAAP: 0.01 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:AAAP' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.16 Max: 0.46
Current: 0.01
0.01
0.46
Debt-to-EBITDA -0.09
NAS:AAAP's Debt-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. NAS:AAAP: -0.09 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:AAAP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -24.59  Med: -1.63 Max: 10.56
Current: -0.09
-24.59
10.56
Piotroski F-Score: 3
Altman Z-Score: 14.69
Beneish M-Score: -3.05
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -23.21
NAS:AAAP's Operating Margin % is ranked higher than
63% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. NAS:AAAP: -23.21 )
Ranked among companies with meaningful Operating Margin % only.
NAS:AAAP' s Operating Margin % Range Over the Past 10 Years
Min: -23.21  Med: -15.42 Max: -3.6
Current: -23.21
-23.21
-3.6
Net Margin % -43.86
NAS:AAAP's Net Margin % is ranked higher than
56% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. NAS:AAAP: -43.86 )
Ranked among companies with meaningful Net Margin % only.
NAS:AAAP' s Net Margin % Range Over the Past 10 Years
Min: -49.09  Med: -20.89 Max: -0.71
Current: -43.86
-49.09
-0.71
ROE % -22.64
NAS:AAAP's ROE % is ranked higher than
61% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. NAS:AAAP: -22.64 )
Ranked among companies with meaningful ROE % only.
NAS:AAAP' s ROE % Range Over the Past 10 Years
Min: -29.57  Med: -12.85 Max: -0.31
Current: -22.64
-29.57
-0.31
ROA % -15.69
NAS:AAAP's ROA % is ranked higher than
64% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. NAS:AAAP: -15.69 )
Ranked among companies with meaningful ROA % only.
NAS:AAAP' s ROA % Range Over the Past 10 Years
Min: -15.69  Med: -7.11 Max: -0.19
Current: -15.69
-15.69
-0.19
ROC (Joel Greenblatt) % -81.04
NAS:AAAP's ROC (Joel Greenblatt) % is ranked higher than
66% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. NAS:AAAP: -81.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:AAAP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -81.04  Med: -24.6 Max: 2.19
Current: -81.04
-81.04
2.19
GuruFocus has detected 5 Warning Signs with Advanced Accelerator Applications SA NAS:AAAP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AAAP's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

AAAP Guru Trades in Q2 2016

Chuck Royce 15,000 sh (New)
» More
Q3 2016

AAAP Guru Trades in Q3 2016

Chuck Royce 15,000 sh (unchged)
» More
Q4 2016

AAAP Guru Trades in Q4 2016

Chuck Royce Sold Out
» More
Q4 2017

AAAP Guru Trades in Q4 2017

Mario Gabelli 102,066 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:AAAP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2017-12-31 New Buy0.05%$65.15 - $81.7 $ 81.635%102,066
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:LSE:BTG, LSE:ABC, SZSE:300347, XKRX:086900, NAS:ARRY, NAS:LGND, SHSE:603233, NAS:FGEN, NAS:LOXO, NAS:TSRO, SHSE:600201, XBRU:ABLX, SZSE:002007, NAS:BPMC, XKRX:084990, XTER:MOR, HKSE:00570, SZSE:000990, NAS:CLVS, SZSE:002603 » details
Traded in other countries:6VAA.Germany,
Headquarter Location:France
Advanced Accelerator Applications SA is a radiopharmaceutical company. It develops, produces and commercializes molecular nuclear medicine diagnostic and therapeutic products.

Advanced Accelerator Applications SA is a French-based radiopharmaceutical company. It develops, produces, and commercializes molecular nuclear medicine diagnostic and therapeutic products. The molecular nuclear medicine is a medical specialty that uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases including cancer. The company includes a portfolio of six diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. Its PET and SPECT are imaging techniques in molecular nuclear diagnostics with applications in clinical oncology, cardiology and neurology. Its other diagnostic product is Gluscan, its branded fluorodeoxyglucose PET imaging agent.

Top Ranked Articles about Advanced Accelerator Applications SA

Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer
Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer
Mario Gabelli’s Top 5 New Buys Investor releases 4th-quarter portfolio
GAMCO Investors leader Mario Gabelli (Trades, Portfolio) released his fourth-quarter portfolio on Monday, listing 40 new positions. Read more...
Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer
Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer
Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer
Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer
Advanced Accelerator Applications Board of Directors Recommends $3.9 Billion All Cash Tender Offer by Novartis

Ratios

vs
industry
vs
history
PB Ratio 11.35
AAAP's PB Ratio is ranked lower than
81% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. AAAP: 11.35 )
Ranked among companies with meaningful PB Ratio only.
AAAP' s PB Ratio Range Over the Past 10 Years
Min: 3.35  Med: 6.53 Max: 11.4
Current: 11.35
3.35
11.4
PS Ratio 23.94
AAAP's PS Ratio is ranked lower than
64% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AAAP: 23.94 )
Ranked among companies with meaningful PS Ratio only.
AAAP' s PS Ratio Range Over the Past 10 Years
Min: 8.02  Med: 12.38 Max: 24.05
Current: 23.94
8.02
24.05
EV-to-EBIT -53.97
AAAP's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. AAAP: -53.97 )
Ranked among companies with meaningful EV-to-EBIT only.
AAAP' s EV-to-EBIT Range Over the Past 10 Years
Min: -95.5  Med: -54 Max: -29.4
Current: -53.97
-95.5
-29.4
EV-to-EBITDA -70.93
AAAP's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. AAAP: -70.93 )
Ranked among companies with meaningful EV-to-EBITDA only.
AAAP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4109.6  Med: -80.8 Max: -38.6
Current: -70.93
-4109.6
-38.6
EV-to-Revenue 22.54
AAAP's EV-to-Revenue is ranked lower than
59% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. AAAP: 22.54 )
Ranked among companies with meaningful EV-to-Revenue only.
AAAP' s EV-to-Revenue Range Over the Past 10 Years
Min: 6.9  Med: 11.6 Max: 22.7
Current: 22.54
6.9
22.7
Current Ratio 5.49
AAAP's Current Ratio is ranked higher than
60% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. AAAP: 5.49 )
Ranked among companies with meaningful Current Ratio only.
AAAP' s Current Ratio Range Over the Past 10 Years
Min: 1.47  Med: 3.08 Max: 6.77
Current: 5.49
1.47
6.77
Quick Ratio 5.22
AAAP's Quick Ratio is ranked higher than
60% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. AAAP: 5.22 )
Ranked among companies with meaningful Quick Ratio only.
AAAP' s Quick Ratio Range Over the Past 10 Years
Min: 1.4  Med: 2.9 Max: 6.57
Current: 5.22
1.4
6.57
Days Inventory 96.90
AAAP's Days Inventory is ranked higher than
63% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. AAAP: 96.90 )
Ranked among companies with meaningful Days Inventory only.
AAAP' s Days Inventory Range Over the Past 10 Years
Min: 73.69  Med: 83.89 Max: 111.81
Current: 96.9
73.69
111.81
Days Sales Outstanding 92.75
AAAP's Days Sales Outstanding is ranked lower than
75% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. AAAP: 92.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
AAAP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 92.75  Med: 109.75 Max: 141.02
Current: 92.75
92.75
141.02
Days Payable 224.56
AAAP's Days Payable is ranked lower than
99.99% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. AAAP: 224.56 )
Ranked among companies with meaningful Days Payable only.
AAAP' s Days Payable Range Over the Past 10 Years
Min: 224.56  Med: 371.61 Max: 713.01
Current: 224.56
224.56
713.01

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 44.61
AAAP's Price-to-Net-Cash is ranked lower than
88% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. AAAP: 44.61 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AAAP' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 10.83  Med: 17.48 Max: 78.18
Current: 44.61
10.83
78.18
Price-to-Net-Current-Asset-Value 23.94
AAAP's Price-to-Net-Current-Asset-Value is ranked lower than
85% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. AAAP: 23.94 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AAAP' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 7.45  Med: 20.26 Max: 100.21
Current: 23.94
7.45
100.21
Price-to-Tangible-Book 15.67
AAAP's Price-to-Tangible-Book is ranked lower than
81% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. AAAP: 15.67 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AAAP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.06  Med: 10.92 Max: 15.79
Current: 15.67
5.06
15.79
Price-to-Median-PS-Value 1.93
AAAP's Price-to-Median-PS-Value is ranked lower than
78% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. AAAP: 1.93 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AAAP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.72  Med: 1.03 Max: 1.93
Current: 1.93
0.72
1.93
Earnings Yield (Greenblatt) % -1.85
AAAP's Earnings Yield (Greenblatt) % is ranked higher than
68% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. AAAP: -1.85 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AAAP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3.4  Med: -1.9 Max: -1
Current: -1.85
-3.4
-1

More Statistics

Revenue (TTM) (Mil) $149.92
EPS (TTM) $ -1.50
52-Week Range $35.11 - 82.74
Shares Outstanding (Mil)44.17 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 143 173 348 462
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.69 -0.37 0.45 0.79
EPS without NRI ($) -0.69 -0.37 0.45 0.79
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}